Celadon Pharmaceuticals PLC
LSE:CEL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Celadon Pharmaceuticals PLC
Common Shares Outstanding
Celadon Pharmaceuticals PLC
Common Shares Outstanding Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Shares Outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Celadon Pharmaceuticals PLC
LSE:CEL
|
Common Shares Outstanding
£85.7m
|
CAGR 3-Years
120%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Croda International PLC
LSE:CRDA
|
Common Shares Outstanding
£139.6m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Science in Sport PLC
LSE:SIS
|
Common Shares Outstanding
£230.6m
|
CAGR 3-Years
20%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Venture Life Group PLC
LSE:VLG
|
Common Shares Outstanding
£128.7m
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
14%
|
|
|
Provexis PLC
LSE:PXS
|
Common Shares Outstanding
£2.3B
|
CAGR 3-Years
2%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
|
A
|
Akanda Corp
NASDAQ:AKAN
|
Common Shares Outstanding
$65.5k
|
CAGR 3-Years
231%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Celadon Pharmaceuticals PLC
Glance View
Summerway Capital Plc engages in acquiring companies or businesses that has the potential for strategic, operational, and performance improvement. The firm is engaged in research, cultivation, manufacturing and supply of cannabinoid-based medicines. The firm is focused on growing indoor hydroponic cannabis initially for the chronic pain market. The company is also focused on improving the quality of life for chronic pain sufferers, as well as exploring the potential of cannabinoid-based medicines for other conditions such as autism. The firm's facility comprises an indoor, closed-loop hydroponic system to ensure cannabis plants are cultivated under a highly specific climate, light and with irrigation control. The firm's subsidiary, LVL Health is a medical cannabis clinic for chronic pain that owns a medicines and healthcare products regulatory agency (MHRA) conditionally approved cannabis trial using cannabis-based medicinal products to treat chronic pain in the United Kingdom.
See Also
What is Celadon Pharmaceuticals PLC's Common Shares Outstanding?
Common Shares Outstanding
85.7m
GBP
Based on the financial report for Dec 31, 2024, Celadon Pharmaceuticals PLC's Common Shares Outstanding amounts to 85.7m GBP.
What is Celadon Pharmaceuticals PLC's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 3Y
120%
Over the last year, the Common Shares Outstanding growth was 7%. The average annual Common Shares Outstanding growth rates for Celadon Pharmaceuticals PLC have been 120% over the past three years .
